Nektar Therapeutics (NKTR) Profit After Tax (2010 - 2026)

Nektar Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$44.9 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 11.75% year-over-year to -$44.9 million in Q1 2026; TTM through Mar 2026 was -$158.2 million, a 18.79% decrease from a year earlier, with the FY2025 full-year figure at -$164.1 million, down 37.92% from the prior year.
• Profit After Tax slipped to -$44.9 million in Q1 2026 per NKTR's latest filing, from -$36.1 million in the prior quarter.
• Across five years, Profit After Tax topped out at $7.3 million in Q4 2024 and bottomed at -$160.7 million in Q2 2022.
• The 5-year median for Profit After Tax is -$45.8 million (2023), against an average of -$57.4 million.
• Across the five-year window, Profit After Tax jumped 117.26% in 2024 and plunged 596.89% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$59.7 million in 2022, then climbed by 29.5% to -$42.1 million in 2023, then jumped by 117.26% to $7.3 million in 2024, then plunged by 596.89% to -$36.1 million in 2025, then retreated by 24.46% to -$44.9 million in 2026.
• Per Business Quant, the three latest NKTR Profit After Tax figures stand at -$44.9 million (Q1 2026), -$36.1 million (Q4 2025), and -$35.5 million (Q3 2025).